HEM Pharma Inc
376270
Company Profile
Business description
HEM Pharma Inc is a microbiome-specialized healthcare company that operates a customized healthcare business and an LBP (Live Biotherapeutic Products) discovery platform business utilizing PMAS (Personalized Pharmaceutical Metal-Analytical Screening), a gut microbiome simulation technology. Its technology includes PMAS, MBR, Multi-omics, Microbiome, and Metabolome.
Contact
558, Handong-ro, Heunghae-eup
F102ho, 102ho
Gyeongsangbuk-do
Buk-gu
Pohang-si
KORT: +82 18994258
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
94
Stocks News & Analysis
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
stocks
New data centre deal for ASX listed REIT
New parternship adds to a growing data centre pipeline in fiscal 2026.
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,036.60 | 29.50 | 0.33% |
| CAC 40 | 8,195.21 | 45.71 | 0.56% |
| DAX 40 | 24,539.34 | 48.93 | 0.20% |
| Dow JONES (US) | 48,382.39 | 319.10 | 0.66% |
| FTSE 100 | 9,951.14 | 19.76 | 0.20% |
| HKSE | 26,338.47 | 707.93 | 2.76% |
| NASDAQ | 23,235.63 | 6.36 | -0.03% |
| Nikkei 225 | 50,339.48 | 187.44 | -0.37% |
| NZX 50 Index | 13,548.42 | 0.29 | 0.00% |
| S&P 500 | 6,858.47 | 12.97 | 0.19% |
| S&P/ASX 200 | 8,727.80 | 27.10 | 0.31% |
| SSE Composite Index | 3,968.84 | 3.72 | 0.09% |